NanoViricides adds Glick as independent board director

NanoViricides (OTCBB:NNVC) Monday announced that Stanley Glick has been appointed as a director of the company and the chairman of its audit committee.

Glick has over forty years of experience in his long career of providing auditing, accounting, tax, and management advisory services, to clients in various industries. He has been a member of several boards of directors for not-for-profit organizations in the Westport, Connecticut area.

Glick is also a member of the American Institute of Certified Public Accountants, The Connecticut Society of Certified Public Accountants, and the New York State Society of Certified Public Accountants.

He holds a Bachelor of Business Administration degree in Accounting from Baruch College of Business (now Baruch College of the City University of New York).

"Stanley’s broad business, accounting and auditing experience will be very helpful to us," NanoViricides president Anil R. Diwan said.

NanoViricides CEO & CFO Eugene Seymour added: "With the appointment of Stanley as an independent director and audit committee chairman, we are now able to significantly improve the Company’s financial oversight and management functioning."

NanoViricides is a development-stage company that is creating special purpose nanomaterials for viral therapy.

The company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them.

NanoViricides is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.